Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Trial Profile

A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Gastrointestinal stromal tumours; Germ cell and embryonal neoplasms; Glioma; Hairy cell leukaemia; Intestinal cancer; Multiple myeloma; Thyroid cancer
  • Focus Therapeutic Use
  • Acronyms ROAR
  • Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Jan 2019 Results (n=33; data cutoff January 3, 2018) from biliary tract cancer patients presented at the 2019 Gastrointestinal Cancers Symposium
    • 04 Dec 2018 Results (n=43, patients with Hairy Cell Leukemia data cut off: Jan 3, 2018) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top